Get the Stockscreener App
32.63
7.76%
2.35
Lenz Therapeutics Inc stock is traded at $32.63, with a volume of 755.97K.
It is up +7.76% in the last 24 hours and down -3.77% over the past month.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision and developing ophthalmic pharmaceutical products.. Its initial focus is the treatment of presbyopia, the inevitable loss of near vision that impacts the daily lives of nearly all people over 45.
See More
Previous Close:
$30.28
Open:
$29.75
24h Volume:
755.97K
Relative Volume:
4.58
Market Cap:
$897.35M
Revenue:
-
Net Income/Loss:
$-69.47M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-73.92M
1W Performance:
+5.36%
1M Performance:
-3.77%
6M Performance:
+80.68%
1Y Performance:
+0.00%
1-Day Range:
$29.05
$33.84
1-Week Range:
$28.90
$33.84
52-Week Range:
$14.42
$38.93
Lenz Therapeutics Inc Stock (LENZ) Company Profile
Name
Lenz Therapeutics Inc
Sector
Industry
Phone
858-925-7000
Address
201 LOMAS SANTA FE DRIVE, SUITE 300, SOLANA BEACH
Compare LENZ with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LENZ
Lenz Therapeutics Inc
|
32.63 | 897.35M | 0 | -69.47M | -73.92M | -5.5973 |
|
VRTX
Vertex Pharmaceuticals Inc
|
397.27 | 102.31B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
701.85 | 77.13B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
623.82 | 37.30B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
245.44 | 31.66B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
113.08 | 27.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Lenz Therapeutics Inc Stock (LENZ) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-27-24 | Initiated | Raymond James | Outperform |
| Aug-12-24 | Initiated | H.C. Wainwright | Buy |
| Apr-15-24 | Initiated | Leerink Partners | Outperform |
| Apr-15-24 | Initiated | William Blair | Outperform |
| Apr-10-24 | Initiated | Citigroup | Buy |
| Mar-27-24 | Initiated | Piper Sandler | Overweight |
| Feb-23-23 | Downgrade | BofA Securities | Neutral → Underperform |
| Feb-23-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-23-23 | Downgrade | Cowen | Outperform → Market Perform |
| Jan-25-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-18-23 | Downgrade | BofA Securities | Buy → Neutral |
| Jan-06-23 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Jan-06-23 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| Sep-15-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-17-22 | Initiated | BMO Capital Markets | Outperform |
| Apr-14-22 | Initiated | BTIG Research | Buy |
| Mar-22-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-18-22 | Initiated | RBC Capital Mkts | Sector Perform |
| Jul-20-21 | Initiated | Morgan Stanley | Overweight |
| Jul-20-21 | Initiated | SVB Leerink | Outperform |
View All
Lenz Therapeutics Inc Stock (LENZ) Latest News
Wellington Management Group LLP Takes $585,000 Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics (NASDAQ:LENZ) Stock Price Down 4.1%Time to Sell? - MarketBeat
BNP Paribas Financial Markets Has $63,000 Stock Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
Presbyopia Therapeutics Market Size was highest in the US among the 7MM, was ~USD 8,039 million, and is expected to increase by 2034 | DelveInsight - Barchart
Presbyopia Therapeutics Market Size was highest in the US among - openPR
LENZ Therapeutics (NASDAQ:LENZ) Trading 5.8% HigherTime to Buy? - MarketBeat
Charles Schwab Investment Management Inc. Has $2.93 Million Stake in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
Charles Schwab Investment Management Inc. Has $2.93 Million Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Sotherly Hotels (NASDAQ:SOHOO) Shares Down 5% – Here’s What Happened - Defense World
XOMA (NASDAQ:XOMAP) Trading Down 0.6% – Should You Sell? - Defense World
Onfolio (NASDAQ:ONFO) Trading 1.1% Higher – Should You Buy? - Defense World
Sumco (OTCMKTS:SUMCF) Shares Up 2.4% – Still a Buy? - Defense World
Cizzle Biotechnology (LON:CIZ) Shares Down 5% – What’s Next? - Defense World
NeurAxis (NASDAQ:NRXS) Stock Price Down 5.3% – Here’s What Happened - Defense World
Glass House Brands (OTCMKTS:GLASF) Shares Up 1.3% – Here’s What Happened - Defense World
The Manufacturers Life Insurance Company Has $740,000 Stock Position in Avadel Pharmaceuticals plc (NASDAQ:AVDL) - Defense World
Century Lithium (CVE:LCE) Trading Down 1.7% – Here’s What Happened - Defense World
Shaftesbury Capital (LON:SHC) Trading Down 1.4% – Here’s What Happened - Defense World
Short Interest in DatChat, Inc. (NASDAQ:DATS) Drops By 56.0% - Defense World
Metal Sky Star Acquisition (NASDAQ:MSSAU) Trading 1.6% Higher – Should You Buy? - Defense World
Indaptus Therapeutics (NASDAQ:INDP) Shares Down 1% – Here’s Why - Defense World
AFC Energy (OTCMKTS:AFGYF) Shares Down 9.7% – What’s Next? - Defense World
Arizona Sonoran Copper (OTC:ASCUF) Trading 1% Higher – Time to Buy? - Defense World
Gusbourne (OTCMKTS:SLLFF) Trading Down 23.9% – Here’s Why - Defense World
The Manufacturers Life Insurance Company Sells 736 Shares of First Advantage Co. (NYSE:FA) - Defense World
The Manufacturers Life Insurance Company Reduces Stock Position in MFA Financial, Inc. (NYSE:MFA) - Defense World
The Manufacturers Life Insurance Company Invests $743,000 in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - Defense World
The Manufacturers Life Insurance Company Sells 3,598 Shares of iShares Semiconductor ETF (NASDAQ:SOXX) - Defense World
The Manufacturers Life Insurance Company Makes New Investment in Vanguard Utilities ETF (NYSEARCA:VPU) - Defense World
CG Oncology (NASDAQ:CGON) vs. LENZ Therapeutics (NASDAQ:LENZ) Head-To-Head Survey - Defense World
Parkman Healthcare Partners LLC Buys New Shares in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
We're Hopeful That LENZ Therapeutics (NASDAQ:LENZ) Will Use Its Cash Wisely - Yahoo Finance
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 4.7%Here's Why - MarketBeat
BBR Partners LLC Increases Position in LENZ Therapeutics, Inc. (NASDAQ:LENZ) - MarketBeat
LENZ Therapeutics: Time For A Pause (NASDAQ:LENZ) - Seeking Alpha
AZEK’s (AZEK) Buy Rating Reiterated at Benchmark - Defense World
102,557 Shares in Kodiak Gas Services, Inc. (NYSE:KGS) Purchased by Victory Capital Management Inc. - Defense World
Top 10 startups in Ophthalmology in San Diego, United States in Nov, 2024 - Tracxn
LENZ Therapeutics, Inc. (NASDAQ:LENZ) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
LENZ Therapeutics, Inc. (LENZ) Is Up 3.37% in One Week: What You Should Know - MSN
Here's Why LENZ Therapeutics, Inc. (LENZ) Is a Great 'Buy the Bottom' Stock Now - MSN
LENZ Therapeutics (NASDAQ:LENZ) Trading Down 6.3%Here's Why - MarketBeat
TANG CAPITAL MANAGEMENT LLC Expands Stake in LENZ Therapeutics I - GuruFocus.com
Presbyopia Treatment Market Set to Reach New Heights with New Therapies and Advancements by 2034 | DelveInsight - The Malaysian Reserve
LENZ Therapeutics (NASDAQ:LENZ) Hits New 1-Year HighWhat's Next? - MarketBeat
LENZ Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
LENZ Therapeutics to Present at 4 Major Healthcare Investor Conferences | LENZ Stock News - StockTitan
Leerink Partnrs Issues Optimistic Estimate for LENZ Earnings - MarketBeat
LENZ Therapeutics’ (LENZ) Buy Rating Reiterated at HC Wainwright - Defense World
Janux Therapeutics’ (JANX) “Buy” Rating Reaffirmed at HC Wainwright - Defense World
Lenz Therapeutics Inc Stock (LENZ) Financials Data
Revenue
Net Income
Cash Flow
EPS
Lenz Therapeutics Inc Stock (LENZ) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Schimmelpennink Evert B. | President, CEO and Secretary |
Jul 22 '24 |
Option Exercise |
1.04 |
45,000 |
46,800 |
45,000 |
| Chevallard Daniel R. | Chief Financial Officer |
May 14 '24 |
Buy |
15.68 |
3,188 |
49,988 |
3,188 |
| MCCOLLUM JAMES W | Director |
May 13 '24 |
Buy |
15.99 |
31,332 |
501,093 |
525,565 |
| RA CAPITAL MANAGEMENT, L.P. | Director |
Mar 21 '24 |
Buy |
15.03 |
998,009 |
15,000,075 |
3,319,339 |
2.88%
2.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):